A wide array of diseases such as
protein deficiency diseases; chronic diseases such as cancer, rheumatoid
arthritis (RA), ankylosing spondylitis, diabetes; infections such as human
immunodeficiency virus (HIV), hepatitis A, hepatitis B, and hepatitis C; and
other medical conditions such as genetic disorders, anemia cases related to
kidney dialysis, and cancer-related anemia are effectively treated using
proteins therapeutic. The growing acceptance from physicians as well as
individuals combined with the recent launches of novel mAbs is driving the
market. Particularly, the increasing use of next-generation mAbs in treating
diseases will have a positive impact on the market. Further, rapid advances in
technologies and the expansion of healthcare in emerging markets is likely to
increase the demand for protein therapeutics. The unexpected episode of the
COVID-19 is further providing development opportunities for the market players.
Molecular Partners AG, a Switzerland-based clinical stage biotechnology
organization, is developing another class of protein therapeutics, called
DARPin, to restrain the multiplication of the infection. However, supply
disruptions will be witnessed in the market due to limited availability of raw
material required for the drug development and restrictions on transportation.
Infinium Global Research’s recent report on the “Protein Therapeutics Market
(Protein Function - Vaccines, Enzymatic and Regulatory, and Protein
Diagnostics; Product Type - Insulin, Erythropoietin, Monoclonal Antibodies,
G-CSF, Interferons, Follicle Stimulating Hormone, and Blood Clotting Factor):
Global Industry Analysis, Trends, Size, Share and Forecasts to 2026”
provides a comprehensive outline of the factors responsible for the growth of
the market.
https://www.infiniumglobalresearch.com/reports/sample-request/1195
Protein-based therapeutics,
including insulin, erythropoietin, monoclonal antibodies, G-CSF, interferons,
follicle stimulating hormone, blood clotting factor are clinically effective in
unprecedented ways. Monoclonal antibodies represent a major segment of the
global protein therapeutics market. mAbs are also used in the formulation of
various biopharmaceutical drugs for the treatment of different diseases such as
cancer, RA, multiple sclerosis, and ulcerative colitis (UC). The increasing use
of mAbs in drug development is contributing to the growth of this market. The
human insulin market is expected to witness high growth during the forecast
period. Factors such as the rising incidence of type 1 and 2 diabetes and
growth in the obese individuals, as well as the older population, will
contribute to this growth. Unhealthy diets and lack of physical activity
fueling the prevalence of diabetes and obesity. The annual growth rate for the
global type 1 diabetes is 3% for children below 14 years of age. Countries such
as the Germany and the UK are the largest contributors to the type 1 diabetes.
The report on the “Global Protein Therapeutics market” offers an in-depth
analysis of the segments such as protein function (vaccines, enzymatic and
regulatory and protein diagnostics), and product Type (insulin, erythropoietin,
monoclonal antibodies, G-CSF, interferons, follicle stimulating hormone and
blood clotting factor).
https://www.infiniumglobalresearch.com/reports/enquiry/1195
Geographically, North America
generated the largest revenue in Protein
Therapeutics Market in 2019 and is expected to continue its dominance
over the forecast years. The rising incidences of chronic diseases such as
heart disease, cancer, and diabetes are the major key driving factor for the
growth of protein therapeutic market. Further, growing awareness of protein
therapeutic applications boosts the market growth in North America region.
Moreover, the Asia Pacific region is anticipated to grow with the highest CAGR
owing to the increasing population and increasing adoption of protein
therapeutic. The region also offers untapped potential in countries such as
India, China, and South Korea.
The protein therapeutics market
is moderately competitive and fragmented with the presence of several
multinational players. The major players Baxter International, F. Hoffmann-La
Roche, Merck, AbbVie Amgen, Novo Nordisk and Eli Lilly are continuously focusing
on improving research and development and facilitate other key strategies to
advance a competitive edge in the market. Growing applications of new
protein-based therapies and rising prevalence of chronic diseases are providing
new growth opportunities for the market players. These manufacturers are also
investing in new drug development to expand product portfolio. Vendors are
forming strategic alliances to manufacture and market drugs. New players are
also entering the market because of the growth opportunities. Any company
engaged in manufacturing and marketing of protein therapeutics that can
effectively treat various disorders, in addition to exhibiting high safety and
efficacy profile, is expected to gain a competitive edge over its peers.
Infinium Global Research’s recent report on the global Protein Therapeutics
Market is an encompassment of such recent developments in the global
marketplace. The report delivers insights into the recent developments by
leading players that have contributed to the growth of the market and also
estimates the impact of recent developments the global market.
